title: Impact of cilostazol on clinical and angiographic outcome after primary stenting for acute myocardial infarction.
abstract: Cilostazol, an antiplatelet drug that also may inhibit smooth muscle proliferation, was given together with aspirin after primary stenting to treat patients with acute myocardial infarction. In a randomized controlled trials of 50 patients, clinical and angiographic outcome at 6 months was significantly improved with cilostazol, depicting a significantly smaller late loss and/or loss index.
authors.affiliation: Department of Medicine (Cardiology), Teikyo University School of Medicine, Tokyo, Japan. mochiai@med.teikyo-u.ac.jp
authors.forename: M
authors.initials: M
authors.lastname: Ochiai
authors.forename: K
authors.initials: K
authors.lastname: Eto
authors.forename: S
authors.initials: S
authors.lastname: Takeshita
authors.forename: N
authors.initials: N
authors.lastname: Yokoyama
authors.forename: A
authors.initials: A
authors.lastname: Oshima
authors.forename: K
authors.initials: K
authors.lastname: Kondo
authors.forename: T
authors.initials: T
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Isshiki
mesh_terms: D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D001241:Aspirin / Q000008:administration & dosage / Q000009:adverse effects; D000077407:Cilostazol; D017023:Coronary Angiography / Q000187:drug effects*; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000628:therapy*; D011292:Premedication; D015607:Stents; D013777:Tetrazoles / Q000008:administration & dosage* / Q000009:adverse effects; D013988:Ticlopidine / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D013777:Tetrazoles; D000077407:Cilostazol; D013988:Ticlopidine; D001241:Aspirin